Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol

Conclusion:
This program is needed because currently once a BGMS product has been cleared for use by the FDA, no systematic postmarket Surveillance Program exists that can monitor analytical performance and detect potential problems. This protocol will allow identification of inaccurate and unreliable BGMSs currently available on the US market. The DTS Surveillance Program will provide BGMS manufacturers a benchmark to understand the postmarket analytical performance of their products. Furthermore, patients, health care professionals, payers, and regulatory agencies will be able to use the results of the study to make informed decisions to, respectively, select, prescribe, finance, and regulate BGMSs on the market.

Source: Journal of Diabetes Science and Technology - May 2, 2016 Category: Endocrinology Authors: Klonoff, D. C., Lias, C., Beck, S., Parkes, J. L., Kovatchev, B., Vigersky, R. A., Arreaza-Rubin, G., Burk, R. D., Kowalski, A., Little, R., Nichols, J., Petersen, M., Rawlings, K., Sacks, D. B., Sampson, E., Scott, S., Seley, J. J., Slingerland, R., Vesp Tags: Original Articles Source Type: research